Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls. by Chenevix-Trench, G. et al.
Br. J. Cancer (1989), 60, 872-874
The 1989
SHORT COMMUNICATION
Restriction fragment length polymorphisms of L-myc and myb in human
leukaemia and lymphoma in relation to age-selected controls
G. Chenevix-Trench, M. Southall & C. Kidson
Queensland Institute ofMedical Research, Bramston Terrace, Brisbane 4006, Australia.
Although genetic susceptibility to cancer is well recognised
(Knudson, 1986) the specific genes involved have not been
identified. Krontiris et al. (1985) first suggested that variation
at proto-oncogene loci might be partly responsible for this
susceptibility. In support of this hypothesis they reported
that rare alleles of the c-Ha-ras gene are more common in
cancer patients, with a variety of tumours, than in healthy
controls. Many groups have conducted similar studies but
even within the same class of tumour contradictory results
have been published (Hayward et al., 1988; Gerhard et al.,
1987). The contradiction may be partly because of the con-
trol group used. It is important that the patient and control
groups be matched for ethnicity, and that the controls have
passed through most of their age of risk. In this way it is
possible to maximise the difference in cancer risk between the
two groups, and therefore the chance of finding an associa-
tion between an allele and the development of a tumour.
Such an association may exist because certain alleles are
more susceptible to transformation by particular carcinogens.
Alternatively, certain alleles may have greater transformation
potential after activation. In both cases, individuals with a
high genetic risk could be subjected to appropriate medical
surveillance.
Most studies in this area have analysed the frequencies of
c-Ha-ras restriction fragment length polymorphisms (RFLPs)
although polymorphisms have been identified at many other
proto-oncogene loci. Most reports have been concerned with
solid tumours rather than haematopoietic neoplasms. In con-
trast, we have explored the genetic variation of two proto-
oncogenes, c-myb and L-myc, in non-Hodgkin's lymphoma
and acute lymphoblastic leukaemia. C-myb is the transform-
ing gene of the avian myeloblastosis virus (AMV). The prod-
uct of the gene is a nuclear DNA binding protein (Moelling
et al., 1985). It is expressed in haematopoetic cells of all
lineages (Westin et al., 1982) and for this reason may play a
role in the differentiation and transformation of these cells.
An EcoRI RFLP of c-myb has been described (Dozier et al.,
1986) but there have been no reports of the allele frequencies
in patients with haematopoietic cancers. L-myc is a member
of the myc family of oncogenes and may, like c-myc, be a
DNA-binding protein (DePinho et al., 1987). Nau et al.
(1985) reported an EcoRI RFLP of L-myc which has subse-
quently been found to have a significant association with the
extent of lung and renal cell cancer metastases (Kawashima
et al., 1988; Kakehi & Yoshida, 1989). In both cases the S
allele is significantly associated with metastases. We wished
to test whether specific alleles of c-myb and L-myc are
associated with non-Hodgkin's lymphoma (NHL) and acute
lymphoblastic leukaemia (ALL). Although it is thought that
the aetiologies of these two diseases may be similar (Berard,
1981), specific risk factors have not been identified.
We used two control groups: namely laboratory workers
unselected except that they had never had cancer (ages un-
known), and geriatric patients (mean age 77 years; range
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53-95 years) who had never had cancer themselves, and had
a negative family history of cancer. The family history in-
formation was obtained by a nurse who did not know the
results of the genotyping. A positive family history was
defined by the occurrence of any cancer, except non-
melanoma skin cancer, in a first degree relative. The mean
age of the 65 NHL patients for which age was known was
58.6 years (range 7-88 years), and for the six ALL patients
was 2.3 years (range 1-4 years). The diagnosis of all patients
was confirmed by histopathology. All the individuals in the
study were of European extraction. Southern blotting was
carried out by the alkaline transfer method (Reed & Mann,
1985) and the blots were hybridised with radiolabelled L-myc
and c-myb probes (Nau et al., 1985; Dozier et al., 1986)
(Figures 1 and 2, Tables I and II). In both cases we detected
the RFLPs as reported (Nau et al., 1985; Dozier et al., 1986)
(Figures I and 2). In addition all blots were hybridised
separately with radiolabelled pUC DNA to distinguish
genetic variation from plasmid contamination (data not
shown). As a further control, the blots were hybridised to a
c-mos probe (which gives a single band in 98% of indi-
viduals) to rule out partial digestion as opposed to genetic
variation (Chenevix-Trench et al., 1989).
The genotype frequencies for c-myb were homogeneous
between the two control groups, between the two patient
groups and between the pooled patient versus the pooled
control groups. Neither was there a significant difference in
the c-myb gene frequencies between the two patient groups
(X2 = 0.904; 0.3 <P<0.5), or between the two control
groups (X2 =0.002; P>0.95). Hence these could be pooled
to compare the frequencies in the total patient group versus
the total control group. The differences were not significant
(X2 = 0.149; 0.5<P<0.7), thereby providing no evidence
that this c-myb polymorphism is involved in the aetiology of
lymphoma and leukaemia.
The L-myc data are more complicated (Table II). It is
obvious that the frequency of the LL homozygotes is higher
among the unselected controls. Indeed there is a significant
heterogeneity of the genotype frequencies between the two
control groups (X2 = 8.82; 0.01 <P<0.02). One biological
explanation of this is that there is differential survival to old
age between genotypes at this locus, such that LL
homozygotes are less likely to reach old age. If this is so, we
should compare the gene frequencies between the combined
patient groups (since there is no difference between them:
2= 0.149; 0.5 <P<0.7) and the unselected controls alone
(since they are more alike in age to our cancer groups). We
then find that the difference is significant (x2 = 5.19;
0.02<P<0.05) with the S allele being more common in the
cancer patients. This implies that the S allele might be one
factor which confers a greater susceptibility to
haematopoietic cancer, just as it appears to influence lung
and renal cancer metastasis (Kawashima et al., 1988; Kakehi
& Yoshida, 1989). One can postulate that this polymorphism
is being maintained in the population by a balance between
its deleterious effects with respect to lung and renal cancer,
NHL and ALL, and its advantageous effects on survival to
old age. Perhaps if the SS or SL individual escapes these
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Figure 1 C-myb alleles. Southern analysis showing the three
genotypes of the C-myb polymorphism. lOjig of genomic DNA
was digested with EcoRI and transferred, after electrophoresis,
to Zetaprobe membrane. This was then hybridised to
radiolabelled pHM2.6 plasmid DNA and washed at high
stringency before a 2-day autoradiographic exposure. Lane 1,
unselected control; lanes 2-5, non-Hodgkin's lymphoma. Al
allele, 2.6 kb band only; A2 allele, 1.5 and 1.1 kb bands.
Presumably the A2 allele contains an EcoRI site which is absent
in the Al allele.
cancers because of other genetic factors, or a favourable
environment, they live longer than the LL homozygotes.
Alternatively, if we assume that there is no coherent
biological explanation for the heterogeneity of the two con-
trol groups we can assume that it is caused by rare sampling
variation. Since we cannot tell whether one or both control
samples are deviating from the population distribution we
pool the genotype totals for the two control sample groups,
and for the two patient samples (the latter are homogeneous,
x2= 0.032; 0.5 <P<0.7), and do a further homogeneity test
on these totals. This is not significant (X2 = 0.648;
0.3 <P<0.5), implying that there is no significant difference
in the genotype frequencies in the patient and control groups.
Therefore we can pool the two control groups, and the two
patient groups, to compare allele frequencies. This difference
is not significant (X2=0.20; 0.5<P<0.7). Further studies
are necessary to determine which of these explanations is
correct.
Among the NHL patients there was no assbociation
between the presence of either L-myc or c-myb allele and a
positive family history of cancer (data not shown). Pooled
across all patient and control groups, we estimate that the
frequency of the c-myb Al allele is 0.432 ± 0.023 and that the
frequency of the L-myc L allele is 0.485 ± 0.021. Goodness of
fit tests show that both these proto-oncogenes are in
Hardy-Weinberg equilibrium (for c-myb X2 = 0.047,
0.8 <P<0.9; and for L-myc X2 = 3.06, 0.05 <P<0.1). This
would be compatible with a neutral polymorphism which
does not affect fitness, or in the case of L-myc, with a
balanced polymorphism maintained by opposing selection
factors. However, it is worth noting that although the
Hardy-Weinberg test is notoriously insensitive to selection
pressures, the L-myc data are approaching a significant
divergence from equilibrium which may indicate that some
undirectional selection, or migration, exists.
Lack of an association between a particular allele and a
disease state does not of course mean that the gene has no
role in the predisposition to the disease. For such an associa-
tion to be detected, the RFLP must detect the predisposing
mutation iteself or be in tight linkage disequilibrium with it.
In addition because NHL and ALL are biologically and
probably aetiologically heterogeneous, the fact that we have
pooled together subtypes of these diseases might have con-
cealed a significant association with particular subtypes. Our
samples were too small to treat the subtypes independently.
Therefore, in conclusion, we have no evidence that this
RFLP of the c-myb locus plays a role in susceptibility to
NHL and ALL although we cannot rule it out. We have
tentative evidence that variation at the L-myc locus plays a
role both in survival to old age, and in susceptibility to these
haematopoietic cancers. However, this result could be due to
sampling fluctuation and should be treated with caution until
replicated.
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Table I C-myb genotypes and gene frequencies incancerpatients and controls
Genotypes Genefrequencies
Al, Al Al, A2 A2, A2 Total Al A2
Patients
NHL 16 (21.6%) 37 (50.0%) 21 (28.3%) 74 0.466 0.534
ALL 2 (11.1%) 9 (50.0%) 7 (38.8%) 18 0.361 0.638
Controls
Geriatrics 18 (17.6%) 51 (50.0%) 33 (32.3%) 102 0.426 0.573
Unselected 7 (17.1%) 20 (48.8%) 14 (34.2%) 41 0.414 0.585
Table II L-myc genotypes and genefrequencies in cancerpatients and controls
Genotypes Geneftequencies
L,L L,S S,S Total L S
Patients
NHL 19 (23.5%) 39 (48.2%) 23 (28.4%) 81 0.475 0.525
ALL 6 (28.6%) 10 (47.6%) 5 (23.8%) 21 0.524 0.476
Controls
Geriatrics 24 (21.4%) 54 (48.2%) 34 (30.4%) 112 0.455 0.544
Unselected 22 (44.9%) 18 (36.7%) 9 (18.4%) 49 0.632 0.367874 G. CHENEVIX-TRENCH et al.
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Figure 2 L-myc alleles. Southern analysis showing the three genotypes of the L-myc polymorphism. IO1lg of genomic DNA was
digested with EcoRI and Soughten blotted onto Zetaprobe membrane. This was hybridised with radiolabelled L-myc probe and
washed at high stringency. The autoradiographic film was exposed for 2 days. Lane 1, unselected control; lane 2, non-Hodgkin's
lymphoma; lanes 3-5 and 7, geriatric control; lane 6, acute lymphoblastic leukaemia. L allele, IO kb band; S allele, 6.0 kb band.
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